ANXA3 and neoplasm: ANXA3 KD was successfully achieved in tumour-derived primary cells, resulting in a reduction of the expression of the proliferation marker MCM2 (Fig. 6c) and significantly reducing proliferation as measured by the EdU assay (Fig. 6d).